Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
December 1, 2008
- Greater Efforts Needed to Promote Use of Generics: Chuikyo
December 1, 2008
- CMIC Aims at Entry into Western Market to Become a Global CRO
December 1, 2008
- Irbesartan Fails to Improve Outcome of Heart Failure Patients with Preserved LVEF
December 1, 2008
- TOPICS／Number of MRs Decreases for First Time in 2007
December 1, 2008
- Subject Enrollment to a PIII Trial of AMG706 Stopped
December 1, 2008
- Combined Sales of TSE 1st Section-Listed 22 Pharmas Up 3.9%
December 1, 2008
- Standard Forms Adopted by Only 70% of Med Institutions Participating in Clinical Trials
December 1, 2008
- VITAL-NET, KSK to Merge to Create 5th Largest Drug Wholesaler
December 1, 2008
- R&D NEWS IN BRIEF
December 1, 2008
- Korosho to Press Large Hospitals to Settle Prices by Year-End
December 1, 2008
- Japan Needs NHI Pricing System That Encourages Innovation: Mr Kinoshita
December 1, 2008
- Advent of Wholesaler Behemoth Will Induce Power Shift
December 1, 2008
- REGULATORY NEWS IN BRIEF
December 1, 2008
- Matsumotokiyoshi to Provide Dispensing Services at 200 Stores
December 1, 2008
- JODA Introduces GL for Online Sales of OTC Drugs
December 1, 2008
- Asahi Kasei Obtains All Rights Related to Naftopidil from Roche Diagnostics
December 1, 2008
- Losses on Sales Expand to 1.6% for Mediceo Paltac
November 24, 2008
- JCR: Net Profits Expected on a Full-year Basis
November 24, 2008
- Alfresa: Sales Up 16.8%, but Profits Down Sharply
November 24, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…